Health
ATPCI: Trimetazidine Fizzles for Post-PCI Angina – Medscape
The antianginal was unable to provide added benefit when added to optimal medical therapy, but one expert questions: Was the right population studied?
Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a nonST-elevated myocardial infarction (MI), results of the ATPCI trial show.
There was no benefit for the composite primary endpoint of cardiac death, hospitalization for cardiac events, or recurrent/persistent angina requiring an addition, switch, or increased dose of antianginal therapies, or requiring coronary angiography (hazard ratio…
-
Noosa News17 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General16 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
General23 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965
-
General19 hours agoMan dies at shopping centre car park at Charlestown following reports of assault